Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 4/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904876 | 0.79 | SIGMAR1 (0.43) | — | |
| SCHEMBL5256851 | 0.77 | PDPK1 (0.39) | — | |
| SCHEMBL10928 | 0.74 | HTR2C (0.36) | — | |
| SCHEMBL1970744 | 0.74 | IDO1 (0.41) | — | |
| SCHEMBL121704 | 0.71 | PDPK1 (0.43) | — | |
| SCHEMBL3290310 | 0.70 | MEN1 (0.56) | MEN1KMT2ANOS1PARP1NOS3 | |
| SCHEMBL2515680 | 0.68 | NOS1 (0.38) | MEN1KMT2ANOS1PARP1NOS3 | |
| SCHEMBL316316 | 0.66 | SRD5A1 (0.41) | — | |
| SCHEMBL6852217 | 0.61 | KMT2A (0.81) | MEN1KMT2ANOS1ALDH1A1KDM4E | |
| SCHEMBL779938 | 0.60 | CHRNB4 (0.46) | MEN1KMT2ABCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137193-B1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2017-08-09 | — | — | EP | claimed |
| EP-2268645-B1 | SUBSTITUTED DIHYDRO, TRIHYDRO AND TETRAHYDRO CYCLOALKYLOXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF AS ALLOSTERIC MODULATORS OF MGLUR | SANOFI SA (FR) | 2014-11-12 | — | — | EP | claimed |
| US-8642603-B2 | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2014-02-04 | — | — | US | claimed |
| US-8207181-B2 | Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2012-06-26 | — | — | US | claimed |
| US-20110077257-A1 | SUBSTITUTED DIHYDRO, TRIHYDRO AND TETRAHYDRO CYCLOALKYLOXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-31 | — | — | US | claimed |
| EP-2268645-A1 | SUBSTITUTED DIHYDRO, TRIHYDRO AND TETRAHYDRO CYCLOALKYLOXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF AS ALLOSTERIC MODULATORS OF MGLUR | Sanofi-Aventis (FR) | 2011-01-05 | — | — | EP | claimed |
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-25 | — | — | US | claimed |
| EP-2137193-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2009-12-30 | — | — | EP | claimed |
| WO-2009110901-A1 | SUBSTITUTED DIHYDRO, TRIHYDRO AND TETRAHYDRO CYCLOALKYLOXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF AS ALLOSTERIC MODULATORS OF MGLUR | SANOFI-AVENTIS (FR) | 2009-09-11 | — | — | WO | claimed |
| WO-2008112483-A2 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2008-09-18 | — | — | WO | claimed |
| EP-0900228-B1 | A METHOD FOR PRODUCING OCTAHYDROFLUORENYL METAL COMPLEXES | DOW CHEMICAL CO (US) | 2002-06-12 | — | — | EP | claimed |
| EP-0900228-A1 | A METHOD FOR PRODUCING OCTAHYDROFLUORENYL METAL COMPLEXES | THE DOW CHEMICAL COMPANY (US) | 1999-03-10 | — | — | EP | claimed |
| WO-1997041134-A1 | A METHOD FOR PRODUCING OCTAHYDROFLUORENYL METAL COMPLEXES | THE DOW CHEMICAL COMPANY (US) | 1997-11-06 | — | — | WO | claimed |
| US-5670680-A | Method for producing octahydrofluorenyl metal complexes | THE DOW CHEMICAL COMPANY (US) | 1997-09-23 | — | — | US | claimed |
| US-3971804-A | ACARICIDES, FUNGICIDES, INSECTICIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| EP-4090655-B1 | PROCESS FOR PREPARING CYCLIC CARBONATES WITH AN EXOCYCLIC VINYLIDENE GROUP | BASF SE (DE) | 2024-03-13 | — | — | EP | disclosed |
| WO-1997041134-A1 | A METHOD FOR PRODUCING OCTAHYDROFLUORENYL METAL COMPLEXES | THE DOW CHEMICAL COMPANY (US) | 1997-11-06 | — | — | WO | disclosed |
| US-5670680-A | Method for producing octahydrofluorenyl metal complexes | THE DOW CHEMICAL COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-5670680-A | Method for producing octahydrofluorenyl metal complexes | THE DOW CHEMICAL COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077257-A1 | SUBSTITUTED DIHYDRO, TRIHYDRO AND TETRAHYDRO CYCLOALKYLOXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | CNR2, CNR1, GRIN2B | MEN1 4347/4885KMT2A 830/4885NOS1 4272/4885 |
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | MEN1 3249/4885KMT2A 963/4885NOS1 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.